TCRX Insider Trading

Insider Ownership Percentage: 8.27%
Insider Buying (Last 12 Months): $266,003.10
Insider Selling (Last 12 Months): $64,008.00

TScan Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at TScan Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TScan Therapeutics Share Price & Price History

Current Price: $7.75
Price Change: Price Decrease of -0.05 (-0.64%)
As of 04/12/2024 01:00 AM ET

This chart shows the closing price history over time for TCRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

TScan Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2023Timothy J BarberichDirectorBuy28,830$4.89$140,978.7066,710View SEC Filing Icon  
12/14/2023Barbara KlenckeDirectorBuy5,000$5.08$25,400.0030,000View SEC Filing Icon  
6/2/2023Timothy J BarberichDirectorBuy37,880$2.63$99,624.4037,880View SEC Filing Icon  
5/31/2023Lynx1 Capital Management LpMajor ShareholderSell25,400$2.52$64,008.005,224,600View SEC Filing Icon  
12/27/2022Brian M. SilverCFOBuy2,842$1.50$4,263.0029,727View SEC Filing Icon  
5/18/2022David P SouthwellCEOBuy25,000$3.59$89,750.00171,569View SEC Filing Icon  
3/24/2022Brian M. SilverCFOBuy15,000$3.40$51,000.00View SEC Filing Icon  
9/23/2021Zoran ZdraveskiInsiderBuy4,716$7.48$35,275.68View SEC Filing Icon  
9/21/2021Brian M. SilverCFOBuy5,000$6.32$31,600.00View SEC Filing Icon  
9/20/2021Gavin MacBeathInsiderBuy4,943$6.22$30,745.46View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for TScan Therapeutics (NASDAQ:TCRX)

82.83% of TScan Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TCRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

TScan Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
3/11/2024Vanguard Group Inc.1,788,152$10.43M0.0%+2.0%3.739%Search for SEC Filing on Google Icon
3/1/2024Goldman Sachs Group Inc.30,285$0.18M0.0%N/A0.063%Search for SEC Filing on Google Icon
2/26/2024Virtu Financial LLC18,418$0.11M0.0%N/A0.039%Search for SEC Filing on Google Icon
2/15/2024Vanguard Group Inc.1,788,152$10.43M0.0%+2.0%3.739%Search for SEC Filing on Google Icon
2/14/2024Balyasny Asset Management L.P.45,986$0.27M0.0%N/A0.096%Search for SEC Filing on Google Icon
2/14/2024Pale Fire Capital SE21,573$0.13M0.0%+30.2%0.045%Search for SEC Filing on Google Icon
2/13/2024Goldman Sachs Group Inc.30,285$0.18M0.0%N/A0.063%Search for SEC Filing on Google Icon
2/12/2024Letko Brosseau & Associates Inc.20,700$0.12M0.0%-36.1%0.043%Search for SEC Filing on Google Icon
2/12/2024Stifel Financial Corp120,400$0.70M0.0%+3.0%0.252%Search for SEC Filing on Google Icon
2/6/2024Charles Schwab Investment Management Inc.22,104$0.13M0.0%N/A0.046%Search for SEC Filing on Google Icon
1/31/2024abrdn plc200,000$1.17M0.0%N/A0.418%Search for SEC Filing on Google Icon
12/18/2023Vanguard Group Inc.1,752,594$4.49M0.0%+28.9%3.664%Search for SEC Filing on Google Icon
11/30/2023American Century Companies Inc.19,212$49K0.0%N/A0.040%Search for SEC Filing on Google Icon
11/14/2023Pale Fire Capital SE16,575$42K0.0%N/A0.035%Search for SEC Filing on Google Icon
11/13/2023Stifel Financial Corp116,900$0.30M0.0%+18.1%0.244%Search for SEC Filing on Google Icon
11/9/2023Letko Brosseau & Associates Inc.32,400$83K0.0%N/A0.068%Search for SEC Filing on Google Icon
8/15/2023Stifel Financial Corp99,000$0.25M0.0%N/A0.409%Search for SEC Filing on Google Icon
8/15/2023BVF Inc. IL2,989,474$7.47M0.2%N/A12.338%Search for SEC Filing on Google Icon
8/14/2023State Street Corp38,500$96K0.0%+60.4%0.159%Search for SEC Filing on Google Icon
8/11/2023Renaissance Technologies LLC147,462$0.37M0.0%+1,171.2%0.609%Search for SEC Filing on Google Icon
8/11/2023BlackRock Inc.1,263,453$3.16M0.0%-16.6%5.214%Search for SEC Filing on Google Icon
8/11/2023Geode Capital Management LLC116,891$0.29M0.0%+16.4%0.482%Search for SEC Filing on Google Icon
8/10/2023Monashee Investment Management LLC400,000$1M0.2%N/A1.651%Search for SEC Filing on Google Icon
7/26/2023Privium Fund Management B.V.15,825$40K0.0%N/A0.065%Search for SEC Filing on Google Icon
5/16/2023State Street Corp24,000$50K0.0%+79.1%0.099%Search for SEC Filing on Google Icon
5/10/2023Simplify Asset Management Inc.546,916$1.15M0.2%N/A2.257%Search for SEC Filing on Google Icon
2/15/2023Tang Capital Management LLC514,655$0.80M0.1%-7.8%2.137%Search for SEC Filing on Google Icon
2/15/2023Millennium Management LLC19,244$31K0.0%N/A0.080%Search for SEC Filing on Google Icon
2/15/2023Morgan Stanley42,175$65K0.0%-34.7%0.175%Search for SEC Filing on Google Icon
11/16/2022Alphabet Inc.1,077,080$3.29M0.2%N/A4.482%Search for SEC Filing on Google Icon
11/15/2022Tang Capital Management LLC557,915$1.70M0.2%-25.4%2.322%Search for SEC Filing on Google Icon
11/15/2022Vanguard Group Inc.257,416$0.79M0.0%+13.9%1.071%Search for SEC Filing on Google Icon
11/4/2022Prudential Financial Inc.11,000$34K0.0%N/A0.046%Search for SEC Filing on Google Icon
11/1/2022Privium Fund Management UK Ltd15,825$48K0.1%N/A0.066%Search for SEC Filing on Google Icon
8/16/2022Jane Street Group LLC10,176$32K0.0%N/A0.042%Search for SEC Filing on Google Icon
8/16/2022Woodline Partners LP132,317$0.42M0.0%-3.4%0.551%Search for SEC Filing on Google Icon
8/12/2022LPL Financial LLC16,000$50K0.0%N/A0.067%Search for SEC Filing on Google Icon
5/17/2022RA Capital Management L.P.1,021,764$2.86M0.1%-18.6%4.299%Search for SEC Filing on Google Icon
5/17/2022Hhlr Advisors LTD.669,513$1.88M0.0%-47.8%2.817%Search for SEC Filing on Google Icon
5/16/2022Woodline Partners LP136,930$0.38M0.0%+37.1%0.576%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC13,300$37K0.0%N/A0.056%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.226,929$0.64M0.0%-4.7%0.955%Search for SEC Filing on Google Icon
5/12/2022BlackRock Inc.1,519,188$4.25M0.0%+1.4%6.392%Search for SEC Filing on Google Icon
4/26/2022Marquette Asset Management LLC28,895$81K0.0%+33.7%0.122%Search for SEC Filing on Google Icon
2/15/2022Deer Management Co. LLC1,245,505$5.61M0.1%N/A5.240%Search for SEC Filing on Google Icon
2/15/2022Adage Capital Partners GP L.L.C.550,000$2.48M0.0%+10.8%2.314%Search for SEC Filing on Google Icon
1/19/2022Marquette Asset Management LLC21,618$97K0.0%N/A0.091%Search for SEC Filing on Google Icon
11/16/2021Schonfeld Strategic Advisors LLC22,200$0.19M0.0%N/A0.093%Search for SEC Filing on Google Icon
11/16/2021Wellington Management Group LLP139,566$1.16M0.0%N/A0.582%Search for SEC Filing on Google Icon
11/15/2021RA Capital Management L.P.1,255,317$10.47M0.1%N/A5.238%Search for SEC Filing on Google Icon
11/15/2021Caas Capital Management LP75,000$0.63M0.0%N/A0.313%Search for SEC Filing on Google Icon
11/12/2021DC Investments Management LLC35,563$0.30M0.6%N/A0.148%Search for SEC Filing on Google Icon
11/12/2021DC Funds LP630,000$5.25M20.6%N/A2.629%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.1,500,577$12.52M0.0%N/A6.261%Search for SEC Filing on Google Icon
11/9/2021Monashee Investment Management LLC100,000$0.83M0.2%N/A0.417%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
TScan Therapeutics logo
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More on TScan Therapeutics

Today's Range

Now: $7.75
Low: $7.49
High: $8.12

50 Day Range

MA: $6.93
Low: $5.55
High: $8.30

52 Week Range

Now: $7.75
Low: $1.62
High: $9.00

Volume

128,946 shs

Average Volume

208,039 shs

Market Capitalization

$371.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Who are the company insiders with the largest holdings of TScan Therapeutics?

TScan Therapeutics' top insider shareholders include:
  1. Lynx1 Capital Management Lp (Major Shareholder)
  2. David P Southwell (CEO)
  3. Timothy J Barberich (Director)
  4. Barbara Klencke (Director)
  5. Brian M Silver (CFO)
Learn More about top insider investors at TScan Therapeutics.